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【Introduction】 
Alzheimer’s disease (AD) is the most common form of dementia in the world 
characterized by the neuropathological hallmarks consisting of an accumulation of 
extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles (NFT), 
followed by neuronal loss. AD incidence increases with population aging and causes a 
heavy burden for families and society. Currently, cholinesterase inhibitors and the N-
methyl-D-aspartate receptor antagonist memantine are the only available options in the 
clinical, but these drugs have only symptomatic relief and do not affect disease 
progression. Therefore, several therapeutics targeting other molecule, such as Aβ and tau, 
are continued to be developed. In the present study, we developed a new therapeutic 
candidate for AD SAK3, a strong TVGCC enhancer and revealed its pharmacokinetics 
and therapeutic effects against AD-related pathology using new AD model mice, AppNL-
F/NL-F (NL-F) and AppNL-G-F/NL-G-F (NL-G-F) knock-in mice. 
 
【Materials and methods】 
We investigated the pharmacokinetics of SAK3¬-d10 and assessed whether SAK3 
administration ameliorated AD-related pathology as followed. 
(i) Mice were orally administered with SAK3¬-d10 (0.5 mg/kg) followed by the plasma 
and brain were collected at some time points. Pharmacokinetics of SAK3¬-d10 were 
revealed by determining the concentration using UPLC-MS/MS systems. Moreover, we 
investigated whether AD pathology influences the pharmacokinetics of SAK3¬-d10 using 
8- and 15-month-old NL-G-F mice. 
(ii) NL-F mice were orally administered with SAK3 (0.5 mg/kg) for 3 months. After 
administration, AD-related pathology including cognitive decline and Aβ deposition were 
analyzed by behavioral tests, ELISA and immunohistochemistry. Additionally, we 
conducted microarray and RT-qPCR analyses to investigate the change of mRNA 
expression by SAK3 administration. 
(iii) NL-G-F mice were acutely administered with SAK3 (0.5 mg/kg) and subjected the 
behavioral tests to assess the cognitive function. Additionally, microdialysis study was 
conducted to investigate the release of Acetylcholine (ACh) in NL-G-F mice. 
(iv) NL-G-F mice were orally administered with SAK3 (0.5 mg/kg) for 3 months. After 
administration, the changes in proteasome activity were assessed. Moreover, 
CaMKII/Rpt6 signaling was investigated by western blot analysis. Furthermore, spine 
abnormalities were analyzed using lucifer yellow injection method. Finally, cognitive 
function was assessed by behavioral tasks. 
 
【Results】 
(i) After administration, SAK3-d10 was rapidly absorbed and reached its peak 
concentration (Cmax: 17.8 ± 1.8 nM) at about 0.65 ± 0.15 h (tmax) and subsequently 
disappeared quickly from the blood. In the brain, SAK3-d10 rapidly reached to Cmax (454.5 
± 66.4 pM) at approximately 0.70 ± 0.12 h. Unexpectedly, brain concentration of SAK3-
d10 was not changed in NL-G-F mice, even at 15-month-old. 
(ii) Chronic SAK3 administration significantly improved the decreased cognitive 
function in NL-F mice. Additionally, Aβ deposition was markedly decreased by chronic 
SAK3 treatment. Microarray and RT-qPCR analyses revealed that SAK3 administration 
ameliorated the declined mRNA expression of serum- and glucocorticoid-induced protein 
kinase 1 (SGK1) in NL-F mice. On the other hand, mRNA expression involved in APP 
metabolism were not changed. 
(iii) Acute SAK3 administration significantly rescued cognitive impairment found in NL-
G-F mice. In microdialysis study, SAK3 treatment increased the decreased the release of 
ACh in the hippocampus of NL-G-F mice to the basal levels of wild-type mice. 
(iv) SAK3 administration significantly increased proteasome activity decreased in NL-
G-F mice brain. The decrease autophosphorylated CaMKII and phosphorylation of Rpt6 
were significantly restored by SAK3 administration. Spine abnormalities including 
decreased spine densities and increased immature spines were ameliorated by SAK3 




In this study, we developed a new AD drug candidate SAK3, a strong TVGCC 
enhancer and revealed its pharmacokinetics and therapeutic effects against AD-related 
pathology using new AD model mice, NL-F and NL-G-F mice. 
Firstly, we observed that SAK3 acute and chronic treatment rescued cognitive 
decline in NL-F and NL-G-F mice. Moreover, chronic SAK3 administration significantly 
decreased Aβ deposition, one of the hallmarks of AD. We found one possible gene, SGK1 
involved in the effects by SAK3 treatment using microarray and RT-qPCR analyses, 
though detailed mechanism remained unclear. In acute administration study, we clarified 
that SAK3 could increase the declined Ach release in the hippocampus of NL-G-F mice, 
contributing to the cognitive improvement. 
Next, we revealed one possible mechanism involved in the therapeutic effects of 
SAK3 against AD pathology. Chronic SAK3 administration improved the decreased 
proteasome activity in NL-G-F mice via activation of CaMKII/Rpt6 signaling. Increased 
proteasome activity accounts for the inhibition of Aβ accumulation and the improvement 
of spine abnormalities, contributing cognitive improvement. 
Taken together, we propose that SAK3 may be a new attractive drug candidate for 













Fig.1 Schematic depicting of the signaling pathway involved in the therapeutic effects by 
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 アルツハイマー病（AD）はアミロイドベータ (Aβ) 沈着と神経原線維変化を病理学的特徴
とする進行性の神経変性疾患である。現在、AD の治療にはコリンエステラーゼ阻害剤で
あるドネペジル、リバスチグミンと NMDA 受容体拮抗薬であるメマンチンが使用されてい





内移行性を確認した。2) 野生型マウスと AD マウス（NL-G-L）マウスの海馬において、ア
セチルコリン遊離を高める。既存薬のドネペジルにはこの効果は見られない。3) SAK3 の
慢性経口投与は CaMKII/Rpt6 シグナルを活性化してプロテアソーム活性を上昇させ、アミ
ロイドプラークの分解を促進することが示唆された。4) プロテアソーム活性化は AD マウ
スで障害されているスパイン形成を改善する効果にも関与すると考えられる。 





を改善することが示唆される。現在、Aβ 沈着抑制を抑制する AD 治療薬はない。SAK3 は
プロテアソームを介した新規メカニズムを明らかにして、臨床開発に進む可能性を示した
点で大いに評価できる。 
 よって，本論文は博士（薬科学）の学位論文として合格と認める。 
